LAUSANNE, Switzerland & SUWON-SI GYEONGGI-DO, South Korea--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s ...
Kyung-Ah Kim, President & CEO of Samsung Bioepis (left) and Zhaoyuan ‘Tony’ Chen, Founder and CEO of Phrontline Biopharma (right) have signed a global strategic partnership agreement to advance ...
Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence ...
Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents Study initiation follows positive ...
SAN DIEGO, November 10, 2025--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the U.S. Food ...
SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an ...
Epithelial cell adhesion molecule (EpCAM) is involved in cancer cell invasion while it acts as a negative regulator of adhesion. EpCAM is overexpressed in several cancer types, such as colorectal, ...
Company Expects to Initiate Buildout of Custom Fill-Finish Line in First Quarter of 2026 in Connection with Previously Announced Long-Term Commitment of up to $1 Billion in U.S. Manufacturing and ...
--Vaxcyte, Inc., a clinical-stage vaccine innovation company, today provided updates on the continued advancement of VAX-31, the Company’ s next-generation 31- valent pneumococcal conjugate vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results